518048-05-0 | N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-2-{2-[(5-methyl-1,3,4-oxadiazol-2-yl)formamido]propan-2-yl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide

Packsize	Purity	Availability	Price	Discounted Price
250mg	97%	in stock	$135.00	$94.00
1g	97%	in stock	$263.00	$184.00
5g	98%	in stock	$1,288.00	$902.00

Description

• Catalog Number: AI51618
• Chemical Name: N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-2-{2-[(5-methyl-1,3,4-oxadiazol-2-yl)formamido]propan-2-yl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide
• CAS Number: 518048-05-0
• Molecular Formula: C20H21FN6O5
• Molecular Weight: 444.4163
• MDL Number: MFCD10698872
• SMILES: Fc1ccc(cc1)CNC(=O)c1nc(n(c(=O)c1O)C)C(NC(=O)c1nnc(o1)C)(C)C

Computed Properties

• Complexity: 836
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 32
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 6
• XLogP3: 1.1

Literature

• Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.

  Antimicrobial agents and chemotherapy 20171201

• Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.

  Antimicrobial agents and chemotherapy 20170801

• Characterization and in vitro activity of a branched peptide boronic acid that interacts with HIV-1 RRE RNA.

  Bioorganic & medicinal chemistry 20160901

• Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors.

  Journal of medicinal chemistry 20151022

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.

  Antimicrobial agents and chemotherapy 20150101

• Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.

  Journal of medicinal chemistry 20140612

• Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase.

  Journal of medicinal chemistry 20140424

• Postexposure protection of macaques from vaginal SHIV infection by topical integrase inhibitors.

  Science translational medicine 20140312

• Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.

  Journal of medicinal chemistry 20140227

• Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20140201

• Synthesis, anti-HIV activity, integrase enzyme inhibition and molecular modeling of catechol, hydroquinone and quinol labdane analogs.

  Bioorganic & medicinal chemistry letters 20140101

• Phenylspirodrimanes with anti-HIV activity from the sponge-derived fungus Stachybotrys chartarum MXH-X73.

  Journal of natural products 20131227

• 6-(1-Benzyl-1H-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach.

  Journal of medicinal chemistry 20131114

• Increasing extracellular protein concentration reduces intracellular antiretroviral drug concentration and antiviral effect.

  AIDS research and human retroviruses 20131101

• Characterization of binding of raltegravir to plasma proteins.

  Antimicrobial agents and chemotherapy 20131001

• Raltegravir flexibility and its impact on recognition by the HIV-1 IN targets.

  Journal of molecular recognition : JMR 20130901

• Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

  Lancet (London, England) 20130824

• Antiretroviral therapy: dolutegravir sets SAIL(ING).

  Lancet (London, England) 20130824

• Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.

  The Lancet. Infectious diseases 20130701

• Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.

  Antimicrobial agents and chemotherapy 20130601

• A novel anti-HIV active integrase inhibitor with a favorable in vitro cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase metabolism profile.

  Antiviral research 20130601

• Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation.

  Proceedings of the National Academy of Sciences of the United States of America 20130521

• Antiviral strategies combining antiretroviral drugs with RNAi-mediated attack on HIV-1 and cellular co-factors.

  Antiviral research 20130401

• Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages.

  Antimicrobial agents and chemotherapy 20130301

• Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles.

  Journal of medicinal chemistry 20130214

• Ruthenium arene complexes as HIV-1 integrase strand transfer inhibitors.

  Journal of inorganic biochemistry 20130101

• The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes.

  PLoS pathogens 20130101

• LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions.

  Retrovirology 20130101

• Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage.

  Retrovirology 20130101

• 6,7-Dihydroxy-1-oxoisoindoline-4-sulfonamide-containing HIV-1 integrase inhibitors.

  Bioorganic & medicinal chemistry letters 20121215

• Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.

  Journal of medical virology 20121201

• Chemokine receptor antagonists.

  Journal of medicinal chemistry 20121126

• Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection.

  AIDS (London, England) 20121113

• [Cardiovascular risk in human immunodeficiency virus-infected patients in Spain. CoRIS cohort, 2011].

  Enfermedades infecciosas y microbiologia clinica 20121101

• A novel ultrasensitive LC-MS/MS assay for quantification of intracellular raltegravir in human cell extracts.

  Journal of pharmaceutical and biomedical analysis 20121101

• A new fluorometric assay for the study of DNA-binding and 3'-processing activities of retroviral integrases and its use for screening of HIV-1 integrase inhibitors.

  Biochimie 20121101

• The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults.

  Journal of acquired immune deficiency syndromes (1999) 20121101

• A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection.

  Journal of acquired immune deficiency syndromes (1999) 20121101

• Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data.

  Antimicrobial agents and chemotherapy 20121101

• LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy.

  Atherosclerosis 20121101

• Next-generation oral preexposure prophylaxis: beyond tenofovir.

  Current opinion in HIV and AIDS 20121101

• Carbamoyl pyridone HIV-1 integrase inhibitors. 1. Molecular design and establishment of an advanced two-metal binding pharmacophore.

  Journal of medicinal chemistry 20121025

• Ultrasensitive liquid chromatography-tandem mass spectrometric methodologies for quantification of five HIV-1 integrase inhibitors in plasma for a microdose clinical trial.

  Analytical chemistry 20121016

• A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.

  AIDS research and human retroviruses 20121001

• Immune recovery and T cell subset analysis during effective treatment with maraviroc.

  The Journal of antimicrobial chemotherapy 20121001

• Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20121001

• Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients.

  The Journal of antimicrobial chemotherapy 20121001

• Risk factors for raltegravir resistance development in clinical practice.

  The Journal of antimicrobial chemotherapy 20121001

• Raltegravir-induced DRESS syndrome.

  Scandinavian journal of infectious diseases 20121001

• Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro.

  Antiviral research 20121001

• The future of integrase inhibitors of HIV-1.

  Current opinion in virology 20121001

• The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.

  AIDS (London, England) 20120924

• Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens.

  AIDS (London, England) 20120910

• Drug resistance mutations of HIV type 1 non-B viruses to integrase inhibitors in treatment-naive patients from sub-saharan countries and discordant interpretations.

  AIDS research and human retroviruses 20120901

• High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs.

  The Journal of antimicrobial chemotherapy 20120901

• Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004).

  Journal of acquired immune deficiency syndromes (1999) 20120901

• The use of HIV-1 integrase inhibitors in antiretroviral naive patients.

  Current opinion in HIV and AIDS 20120901

• Resistance to HIV integrase inhibitors.

  Current opinion in HIV and AIDS 20120901

• Pharmacology of HIV integrase inhibitors.

  Current opinion in HIV and AIDS 20120901

• A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy.

  AIDS patient care and STDs 20120901

• Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy.

  Bioorganic & medicinal chemistry 20120901

• HIV integrase inhibitors in ART-experienced patients.

  Current opinion in HIV and AIDS 20120901

• Tolerability of HIV integrase inhibitors.

  Current opinion in HIV and AIDS 20120901

• Synthetic approaches and pharmacological activity of 1,3,4-oxadiazoles: a review of the literature from 2000-2012.

  Molecules (Basel, Switzerland) 20120827

• Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens.

  AIDS (London, England) 20120824

• Short communication: lack of correlation between UGT1A1*6, *28 genotypes, and plasma raltegravir concentrations in Japanese HIV type 1-infected patients.

  AIDS research and human retroviruses 20120801

• Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.

  British journal of clinical pharmacology 20120801

• Pharmacokinetic and safety of raltegravir in pregnancy.

  European journal of clinical pharmacology 20120801

• Understanding the effect of drug-resistant mutations of HIV-1 intasome on raltegravir action through molecular modeling study.

  Molecular bioSystems 20120801

• Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

  JAMA 20120725

• Testing superiority at interim analyses in a non-inferiority trial.

  Statistics in medicine 20120710

• Low frequency of skin reactions in a cohort of patients on raltegravir.

  The Journal of antimicrobial chemotherapy 20120701

• In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen.

  Antiviral research 20120701

• Update on raltegravir and the development of new integrase strand transfer inhibitors.

  Southern medical journal 20120701

• Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors.

  International journal of STD & AIDS 20120701

• Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use.

  Drugs 20120618

• [Characteristics of human immunodeficiency virus-1 infected children receiving highly active antiretroviral therapy: a cross-sectional study].

  Anales de pediatria (Barcelona, Spain : 2003) 20120601

• Development of an AlphaScreen-based HIV-1 integrase dimerization assay for discovery of novel allosteric inhibitors.

  Journal of biomolecular screening 20120601

• Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.

  Antimicrobial agents and chemotherapy 20120601

• Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen.

  The Journal of antimicrobial chemotherapy 20120601

• A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults.

  Journal of acquired immune deficiency syndromes (1999) 20120601

• A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.

  PLoS pathogens 20120601

• [Undetectable viral load after the addition of raltegravir in a 36 week pregnant adolescent with high-level HIV viraemia].

  Anales de pediatria (Barcelona, Spain : 2003) 20120501

• Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.

  Gastroenterology 20120501

• Modeling HIV-1 drug resistance as episodic directional selection.

  PLoS computational biology 20120501

• Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.

  Journal of acquired immune deficiency syndromes (1999) 20120415

• [Leucoencephalopathy in a patient with type I human immunodeficiency virus (HIV-1) infection and symptoms of a hypertensive emergency].

  Enfermedades infecciosas y microbiologia clinica 20120401

• Discovery of drugs that possess activity against feline leukemia virus.

  The Journal of general virology 20120401

• Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence.

  Journal of acquired immune deficiency syndromes (1999) 20120401

• Hydroxyl may not be indispensable for raltegravir: Design, synthesis and SAR Studies of raltegravir derivatives as HIV-1 inhibitors.

  European journal of medicinal chemistry 20120401

• Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting.

  Therapeutic drug monitoring 20120401

• Role of raltegravir in HIV-1 management.

  The Annals of pharmacotherapy 20120401

• [Integrase inhibitors and CCR5 receptor antagonists].

  Nihon rinsho. Japanese journal of clinical medicine 20120401

• A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120315

• Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir.

  AIDS (London, England) 20120313

• Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards.

  AIDS (London, England) 20120313

• Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients.

  Journal of clinical pharmacology 20120301

• No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20120301

• Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials.

  HIV medicine 20120301

• Elvitegravir: a once-daily inhibitor of HIV-1 integrase.

  Expert opinion on investigational drugs 20120301

• Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.

  The Pediatric infectious disease journal 20120301

• [Allogeneic stem cell transplantation for acute myeloid leukemia and HIV infection--case 3/2012].

  Deutsche medizinische Wochenschrift (1946) 20120301

• LEDGF/p75-independent HIV-1 replication demonstrates a role for HRP-2 and remains sensitive to inhibition by LEDGINs.

  PLoS pathogens 20120301

• CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.

  PLoS medicine 20120301

• Homology model-guided 3D-QSAR studies of HIV-1 integrase inhibitors.

  Journal of chemical information and modeling 20120227

• Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy.

  AIDS (London, England) 20120220

• [Raltegravir in HIV-infected patients with high vascular risk].

  Medicina clinica 20120218

• Molecular mechanism of HIV-1 integrase-vDNA interactions and strand transfer inhibitor action: a molecular modeling perspective.

  Journal of computational chemistry 20120215

• Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.

  The Journal of infectious diseases 20120215

• Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations.

  AIDS research and human retroviruses 20120201

• Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection.

  HIV medicine 20120201

• Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies.

  Cancer chemotherapy and pharmacology 20120201

• Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients.

  Pharmacological research 20120201

• Bicyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.

  Chemical biology & drug design 20120201

• Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs.

  Current infectious disease reports 20120201

• Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects.

  The Journal of antimicrobial chemotherapy 20120201

• Low-level viraemia on HAART: significance and management.

  Current opinion in infectious diseases 20120201

• In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.

  Antiviral research 20120201

• Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection.

  PLoS pathogens 20120201

• Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection.

  Pharmacotherapy 20120201

• Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.

  AIDS (London, England) 20120114

• Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy.

  Neurology 20120110

• Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance.

  Haemophilia : the official journal of the World Federation of Hemophilia 20120101

• Antiviral effect of raltegravir on HTLV-1 carriers.

  The Journal of antimicrobial chemotherapy 20120101

• Adherence and preexisting major protease inhibitor resistance mutations are associated with virologic failure of a dual-class antiretroviral regimen with inhibitors of HIV-1 viral protease and integrase.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20120101

• Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

  The Lancet. Infectious diseases 20120101

• Elvitegravir: a once daily alternative to raltegravir.

  The Lancet. Infectious diseases 20120101

• Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.

  Expert review of anti-infective therapy 20120101

• Design and synthesis of novel β-diketo derivatives as HIV-1 integrase inhibitors.

  Bioorganic & medicinal chemistry 20120101

• Diketoacid inhibitors of HIV-1 integrase: from L-708,906 to raltegravir and beyond.

  Current medicinal chemistry 20120101

• Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN.

  Epilepsia 20120101

• Immunologic effectiveness of maraviroc- and raltegravir-containing regimens (R+M+) versus raltegravir-based regimens that do not include maraviroc (R+M-).

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20120101

• Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.

  Antiviral therapy 20120101

• HIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selection.

  PLoS computational biology 20120101

• Targets for inhibition of HIV replication: entry, enzyme action, release and maturation.

  Intervirology 20120101

• Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.

  Antiviral therapy 20120101

• A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs.

  PloS one 20120101

• Novel agents for the treatment of HIV-2 infection.

  Antiviral therapy 20120101

• Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings.

  HIV/AIDS (Auckland, N.Z.) 20120101

• The use of preexposure treatments for HIV prophylaxis.

  HIV/AIDS (Auckland, N.Z.) 20120101

• Antiviral activity of recombinant ankyrin targeted to the capsid domain of HIV-1 Gag polyprotein.

  Retrovirology 20120101

• HIV-associated gastric natural killer/T-cell lymphoma.

  International journal of STD & AIDS 20120101

• Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States.

  PloS one 20120101

• Impaired maraviroc and raltegravir clearance in a human immunodeficiency virus-infected patient with end-stage liver disease and renal impairment: a management dilemma.

  Pharmacotherapy 20120101

• In-depth characterization of viral isolates from plasma and cells compared with plasma circulating quasispecies in early HIV-1 infection.

  PloS one 20120101

• Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA.

  PloS one 20120101

• Conference highlights of the 5th international workshop on HIV persistence during therapy, 6-9 December 2011, St. Maartin, West Indies.

  AIDS research and therapy 20120101

• Controversies in HIV cure research.

  Journal of the International AIDS Society 20120101

• Inhibition of HIV-1 replication with stable RNAi-mediated knockdown of autophagy factors.

  Virology journal 20120101

• Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.

  Intervirology 20120101

• Urgent liver transplantation for nevirapine-induced acute liver failure: report of a case and review of the literature.

  Annals of transplantation 20120101

• Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions.

  Clinical & developmental immunology 20120101

• Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection.

  PloS one 20120101

• BF integrase genes of HIV-1 circulating in São Paulo, Brazil, with a recurrent recombination region.

  PloS one 20120101

• HIV RNA suppression and immune restoration: can we do better?

  Clinical & developmental immunology 20120101

• Novel therapeutic strategies targeting HIV integrase.

  BMC medicine 20120101

• HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.

  International journal of hepatology 20120101

• Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program.

  HIV clinical trials 20120101

• Molecular Understanding of HIV-1 Latency.

  Advances in virology 20120101

• An overview of the evidence and mechanisms of herb-drug interactions.

  Frontiers in pharmacology 20120101

• Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals.

  PloS one 20120101

• Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.

  PloS one 20120101

• A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.

  HIV clinical trials 20120101

• Impact of short-term HAART initiated during the chronic stage or shortly post-exposure on SIV infection of male genital organs.

  PloS one 20120101

• Susceptibility of human lymphoid tissue cultured ex vivo to xenotropic murine leukemia virus-related virus (XMRV) infection.

  PloS one 20120101

• Antiretroviral drugs: critical issues and recent advances.

  Indian journal of pharmacology 20120101

• Hypophosphatemic Osteomalacia Associated with Tenofovir: a Multidisciplinary Approach is Required.

  Mediterranean journal of hematology and infectious diseases 20120101

• Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era.

  Patient preference and adherence 20120101

• Unprocessed viral DNA could be the primary target of the HIV-1 integrase inhibitor raltegravir.

  PloS one 20120101

• 96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience.

  PloS one 20120101

• Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations.

  PloS one 20120101

• Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.

  HIV clinical trials 20120101

• The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series.

  Antiviral therapy 20120101

• Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.

  PloS one 20120101

• Prolonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 'deep' sequencing.

  PloS one 20120101

• Elevated liver enzymes resulting from an interaction between Raltegravir and Panax ginseng: a case report and brief review.

  Drug metabolism and drug interactions 20120101

• Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors.

  Journal of medicinal chemistry 20111222

• Interfacial inhibitors: targeting macromolecular complexes.

  Nature reviews. Drug discovery 20111216

• Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.

  Journal of acquired immune deficiency syndromes (1999) 20111215

• Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy.

  The Journal of infectious diseases 20111215

• Autoimmune disease: A role for new anti-viral therapies?

  Autoimmunity reviews 20111201

• Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.

  The Lancet. Infectious diseases 20111201

• The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.

  The Journal of antimicrobial chemotherapy 20111201

• Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.

  The Journal of infectious diseases 20111201

• Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial.

  Drugs in R&D 20111201

• A sensitive liquid chromatography coupled with mass spectrometry method for the intracellular and plasma quantification of raltegravir after solid-phase extraction.

  The Journal of pharmacy and pharmacology 20111201

• Cost-effectiveness of raltegravir in HIV/AIDS.

  Expert review of pharmacoeconomics & outcomes research 20111201

• Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results.

  Current HIV research 20111201

• Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to?

  The Indian journal of medical research 20111201

• Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.

  AIDS (London, England) 20111128

• Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient.

  AIDS (London, England) 20111128

• HIV-1 integrase inhibitors: a review of their chemical development.

  Antiviral chemistry & chemotherapy 20111117

• Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial.

  The Journal of infectious diseases 20111115

• How much do antiretroviral drugs penetrate into the central nervous system?

  Journal of medicine and life 20111114

• Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).

  AIDS (London, England) 20111113

• Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir.

  AIDS (London, England) 20111113

• The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes.

  Medical microbiology and immunology 20111101

• Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes.

  Antiviral research 20111101

• In vitro activity of antiretroviral drugs against Plasmodium falciparum.

  Antimicrobial agents and chemotherapy 20111101

• MK-0536 inhibits HIV-1 integrases resistant to raltegravir.

  Antimicrobial agents and chemotherapy 20111101

• 3-Hydroxy-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-ones as new HIV-1 integrase inhibitors WO2011046873 A1.

  Expert opinion on therapeutic patents 20111101

• Raltegravir dosage adjustment in HIV-infected patients receiving etravirine.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20111101

• Switching between raltegravir resistance pathways analyzed by deep sequencing.

  AIDS (London, England) 20111023

• Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.

  Journal of clinical pharmacology 20111001

• Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572).

  Molecular pharmacology 20111001

• 4-[1-(4-Fluorobenzyl)-4-hydroxy-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acid as a prototype to develop dual inhibitors of HIV-1 integration process.

  Antiviral research 20111001

• Antiretroviral therapy for children in resource-limited settings: current regimens and the role of newer agents.

  Paediatric drugs 20111001

• Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20111001

• [Raltegravir in a special case: patient with HIV and Burkitt's lymphoma].

  Deutsche medizinische Wochenschrift (1946) 20111001

• Deep molecular characterization of HIV-1 dynamics under suppressive HAART.

  PLoS pathogens 20111001

• [Fulminant hepatic failure by hepatitis B virus in a patient with human immunodeficiency virus infection: report of one case].

  Revista medica de Chile 20111001

• [Human immunodeficiency virus and Chagas disease coinfection treated successfully with benznidazole and a raltegravir-based antiretroviral regimen: a case report].

  Medicina clinica 20110910

• A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States.

  AIDS care 20110901

• Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.

  The Journal of antimicrobial chemotherapy 20110901

• IL-15 delays suppression and fails to promote immune reconstitution in virally suppressed chronically SIV-infected macaques.

  Blood 20110901

• Inhibition of Feline leukemia virus replication by the integrase inhibitor Raltegravir.

  Veterinary microbiology 20110826

• Ethyl malonate amides: a diketo acid offspring fragment for HIV integrase inhibition.

  Bioorganic & medicinal chemistry 20110815

• DRESS syndrome associated with raltegravir.

  Dermatology online journal 20110815

• Microwave assisted organic synthesis (MAOS) of small molecules as potential HIV-1 integrase inhibitors.

  Molecules (Basel, Switzerland) 20110811

• New first and second generation inhibitors of human immunodeficiency virus-1 integrase.

  Expert opinion on therapeutic patents 20110801

• Pharmacokinetics of the raltegravir/maraviroc/etravirine combination.

  The Journal of antimicrobial chemotherapy 20110801

• Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.

  Antiviral research 20110801

• A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study).

  AIDS (London, England) 20110731

• HIV-1 integrase strand transfer inhibitors stabilize an integrase-single blunt-ended DNA complex.

  Journal of molecular biology 20110729

• Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies.

  AIDS (London, England) 20110717

• Short communication: dynamic constraints on the second phase compartment of HIV-infected cells.

  AIDS research and human retroviruses 20110701

• Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.

  AIDS research and human retroviruses 20110701

• Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.

  The Journal of antimicrobial chemotherapy 20110701

• Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.

  The Journal of antimicrobial chemotherapy 20110701

• Pharmacophore development and docking studies of the hiv-1 integrase inhibitors derived from N-methylpyrimidones, Dihydroxypyrimidines, and bicyclic pyrimidinones.

  Chemical biology & drug design 20110701

• Drug resistance mutations in patients infected with HIV-2 living in Spain.

  The Journal of antimicrobial chemotherapy 20110701

• Effect of continuous venovenous hemodiafiltration on darunavir and raltegravir exposure after administration via a gastroduodenal tube.

  AIDS (London, England) 20110619

• Common adverse effects of antiretroviral therapy for HIV disease.

  American family physician 20110615

• Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation.

  Journal of clinical pharmacology 20110601

• Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20110601

• Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C.

  The Journal of antimicrobial chemotherapy 20110601

• Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers.

  The Journal of antimicrobial chemotherapy 20110601

• Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.

  Antiviral research 20110601

• Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.

  AIDS (London, England) 20110601

• Binding modes of diketo-acid inhibitors of HIV-1 integrase: a comparative molecular dynamics simulation study.

  Journal of molecular graphics & modelling 20110601

• Management of HIV infection in treatment-naive patients: a review of the most current recommendations.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110601

• Raltegravir in pregnancy: a case series presentation.

  International journal of STD & AIDS 20110601

• Methyl 2-(2-{[(benz-yloxy)carbon-yl]amino}-propan-2-yl)-5-hy-droxy-6-meth-oxy-pyrimidine-4-carboxyl-ate.

  Acta crystallographica. Section E, Structure reports online 20110601

• Methyl 2-(2-{[(benz-yloxy)carbon-yl]amino}-propan-2-yl)-5-hy-droxy-6-oxo-1,6-dihydro-pyrimidine-4-carboxyl-ate.

  Acta crystallographica. Section E, Structure reports online 20110601

• Gammaretroviral vectors: biology, technology and application.

  Viruses 20110601

• Targeting HTLV-1 activation of NFκB in mouse models and ATLL patients.

  Viruses 20110601

• [Long-term therapy strategy with raltegravir. Appropriate in all illness phases].

  MMW Fortschritte der Medizin 20110505

• Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease.

  Joint, bone, spine : revue du rhumatisme 20110501

• Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors.

  Journal of acquired immune deficiency syndromes (1999) 20110501

• HIV-1 integrase inhibitor resistance and its clinical implications.

  The Journal of infectious diseases 20110501

• [Characteristics of antiretroviral drugs].

  Enfermedades infecciosas y microbiologia clinica 20110501

• Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples.

  Bioanalysis 20110501

• CTL escape mediated by proteasomal destruction of an HIV-1 cryptic epitope.

  PLoS pathogens 20110501

• Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA.

  PLoS pathogens 20110501

• Foamy virus biology and its application for vector development.

  Viruses 20110501

• Reply to 'Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients'.

  AIDS (London, England) 20110424

• 3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integrase.

  Journal of medicinal chemistry 20110414

• Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir.

  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20110401

• Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine.

  Journal of acquired immune deficiency syndromes (1999) 20110401

• S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges.

  Expert opinion on investigational drugs 20110401

• Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro.

  The Journal of antimicrobial chemotherapy 20110401

• Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers.

  The Journal of antimicrobial chemotherapy 20110401

• Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women.

  British journal of clinical pharmacology 20110401

• A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.

  The Journal of infectious diseases 20110401

• A stochastic model of latently infected cell reactivation and viral blip generation in treated HIV patients.

  PLoS computational biology 20110401

• Neutral actions of Raltegravir on adipogenesis, glucose metabolism and lipolysis in 3T3-L1 adipocytes.

  Current HIV research 20110401

• Clinical management of HIV drug resistance.

  Viruses 20110401

• A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation.

  Journal of pharmaceutical and biomedical analysis 20110325

• Structural biology of retroviral DNA integration.

  Virology 20110315

• Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia.

  AIDS (London, England) 20110313

• Severe insomnia related to high concentrations of raltegravir.

  AIDS (London, England) 20110313

• Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics.

  Journal of clinical pharmacology 20110301

• Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction.

  Pharmacological research 20110301

• Levels of adherence required for virologic suppression among newer antiretroviral medications.

  The Annals of pharmacotherapy 20110301

• Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.

  The Annals of pharmacotherapy 20110301

• Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.

  Annals of the New York Academy of Sciences 20110301

• Allosteric inhibitor development targeting HIV-1 integrase.

  ChemMedChem 20110207

• Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir.

  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20110201

• Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.

  Drug metabolism and disposition: the biological fate of chemicals 20110201

• Emerging antiretroviral drug interactions.

  The Journal of antimicrobial chemotherapy 20110201

• Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.

  The Journal of antimicrobial chemotherapy 20110201

• HIV-1 integrase strand-transfer inhibitors: design, synthesis and molecular modeling investigation.

  European journal of medicinal chemistry 20110201

• Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass spectrometric method.

  Journal of mass spectrometry : JMS 20110201

• Initial results reported on raltegravir once-daily dosing.

  AIDS patient care and STDs 20110201

• Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART.

  PLoS pathogens 20110201

• Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure.

  PLoS pathogens 20110201

• An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).

  Journal of medicinal chemistry 20110113

• Recent advances in antiretroviral drugs.

  Expert opinion on pharmacotherapy 20110101

• Natural polymorphisms of HIV-1 CRF01_AE integrase coding region in ARV-naïve individuals in Cambodia, Thailand and Vietnam: an ANRS AC12 working group study.

  Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 20110101

• Indications for the use of next-generation antiretroviral drugs in current clinical practice.

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20110101

• Long-term safety from the raltegravir clinical development program.

  Current HIV research 20110101

• Human Herpesvirus-8 Infection Associated with Kaposi Sarcoma, Multicentric Castleman's Disease, and Plasmablastic Microlymphoma in a Man with AIDS: A Case Report with Review of Pathophysiologic Processes.

  Pathology research international 20110101

• Finding a cure for HIV: will it ever be achievable?

  Journal of the International AIDS Society 20110101

• Clinical use of CCR5 inhibitors in HIV and beyond.

  Journal of translational medicine 20110101

• Evidence and controversies on the role of XMRV in prostate cancer and chronic fatigue syndrome.

  Reviews in medical virology 20110101

• A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa.

  Journal of the International AIDS Society 20110101

• Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature.

  Journal of medical case reports 20110101

• Penicillium marneffei Infection in AIDS.

  Pathology research international 20110101

• HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen?

  Clinical drug investigation 20110101

• Management of HIV-1 associated hepatitis in patients with acquired immunodeficiency syndrome: role of a successful control of viral replication.

  AIDS research and therapy 20110101

• Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort.

  PloS one 20110101

• Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV.

  AIDS research and therapy 20110101

• The costs of full suppression of plasma HIV RNA in highly antiretroviral-experienced patients.

  AIDS reviews 20110101

• Use of maraviroc-, raltegravir-, and etravirine-containing regimens in treatment-experienced patients: a case-series study.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20110101

• Driving a decade of change: HIV/AIDS, patents and access to medicines for all.

  Journal of the International AIDS Society 20110101

• Interaction between antiretroviral drugs and acenocoumarol.

  Antiviral therapy 20110101

• Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient.

  Antiviral therapy 20110101

• HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients.

  Virology journal 20110101

• HIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirs.

  PloS one 20110101

• Comparison of intima-media thickness and ophthalmic artery resistance index for assessing subclinical atherosclerosis in HIV-1-infected patients.

  Cardiovascular ultrasound 20110101

• Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial.

  PloS one 20110101

• Activation of latent HIV using drug-loaded nanoparticles.

  PloS one 20110101

• Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings.

  AIDS research and treatment 20110101

• Outcomes of Universal Access to Antiretroviral Therapy (ART) in Georgia.

  AIDS research and treatment 20110101

• Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa.

  AIDS research and treatment 20110101

• Multilevel Parallelization of AutoDock 4.2.

  Journal of cheminformatics 20110101

• A functional role for ADAM10 in human immunodeficiency virus type-1 replication.

  Retrovirology 20110101

• Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study.

  AIDS research and therapy 20110101

• Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis.

  Malaria journal 20110101

• Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects.

  PloS one 20110101

• Cellular HIV-1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration.

  BMC infectious diseases 20110101

• HIV and HAART-Associated Dyslipidemia.

  The open cardiovascular medicine journal 20110101

• HIVToolbox, an integrated web application for investigating HIV.

  PloS one 20110101

• A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice.

  PloS one 20110101

• Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.

  HIV clinical trials 20110101

• Rapid turnover of 2-LTR HIV-1 DNA during early stage of highly active antiretroviral therapy.

  PloS one 20110101

• Patterns of resistance development with integrase inhibitors in HIV.

  Infection and drug resistance 20110101

• Early mortality and AIDS progression despite high initial antiretroviral therapy adherence and virologic suppression in Botswana.

  PloS one 20110101

• Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV.

  AIDS research and therapy 20110101

• The role of unintegrated DNA in HIV infection.

  Retrovirology 20110101

• SIV antigen immunization induces transient antigen-specific T cell responses and selectively activates viral replication in draining lymph nodes in retroviral suppressed rhesus macaques.

  Retrovirology 20110101

• HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.

  PloS one 20110101

• Pre-exposure prophylaxis of HIV.

  Indian journal of sexually transmitted diseases and AIDS 20110101

• Long-term outcomes of liver transplant patients with human immunodeficiency virus infection and end-stage-liver-disease: single center experience.

  European journal of medical research 20110101

• The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment.

  Retrovirology 20110101

• Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.

  Patient preference and adherence 20110101

• G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.

  Retrovirology 20110101

• A crystal structure of the catalytic core domain of an avian sarcoma and leukemia virus integrase suggests an alternate dimeric assembly.

  PloS one 20110101

• Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?

  PloS one 20110101

• Nephrotoxicity of HAART.

  AIDS research and treatment 20110101

• Pathogenicity and rapid growth kinetics of feline immunodeficiency virus are linked to 3' elements.

  PloS one 20110101

• Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART.

  Antiviral therapy 20110101

• Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.

  Antiviral therapy 20110101

• Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials.

  PloS one 20110101

• A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults.

  PloS one 20110101

• Successful tacrolimus treatment following renal transplant in a HIV-infected patient with raltegravir previously treated with a protease inhibitor based regimen.

  Drug metabolism and drug interactions 20110101

• A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries.

  Globalization and health 20110101

• Non-Enzymatic Functions of Retroviral Integrase: The Next Target for Novel Anti-HIV Drug Development.

  Frontiers in microbiology 20110101

• Meeting the demand for more sophisticated study designs. A proposal for a new type of clinical trial: the hybrid design.

  BMJ open 20110101

• Resource utilization and cost-effectiveness of counselor- vs. provider-based rapid point-of-care HIV screening in the emergency department.

  PloS one 20110101

• Conference highlights of the 15th International Conference on Human Retrovirology: HTLV and related retroviruses, 4-8 June 2011, Leuven, Gembloux, Belgium.

  Retrovirology 20110101

• Molecular dynamics simulations and drug discovery.

  BMC biology 20110101

• Comparative effectiveness of efavirenz, protease inhibitors, and raltegravir-based regimens as first-line treatment for HIV-infected adults: a mixed treatment comparison.

  HIV clinical trials 20110101

• 96-week results of a pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: the SHIELD trial.

  HIV clinical trials 20110101

• An autoimmune disease prevented by anti-retroviral drugs.

  Retrovirology 20110101

• A whole genome screen for HIV restriction factors.

  Retrovirology 20110101

• It is time to consider third-line options in antiretroviral-experienced paediatric patients?

  Journal of the International AIDS Society 20110101

• 8-Modified-2'-deoxyadenosine analogues induce delayed polymerization arrest during HIV-1 reverse transcription.

  PloS one 20110101

• Role of raltegravir in the management of HIV-1 infection.

  HIV/AIDS (Auckland, N.Z.) 20110101

• Implications of integrase inhibitors for HIV-infected transplantation recipients: raltegravir and dolutegravir (S/GSK 1349572).

  Bioscience trends 20110101

• Tenofovir induced acute kidney injury in a patient with unilateral renal agenesis despite initially non-impaired renal function.

  European journal of medical research 20110101

• Definition of the viral targets of protective HIV-1-specific T cell responses.

  Journal of translational medicine 20110101

• Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).

  Antiviral therapy 20110101

• Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract.

  Antiviral therapy 20110101

• Cost-effectiveness analysis of initial HIV treatment under Italian guidelines.

  ClinicoEconomics and outcomes research : CEOR 20110101

• Applications of next-generation sequencing technologies to diagnostic virology.

  International journal of molecular sciences 20110101

• Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected.

  PloS one 20110101

• Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.

  HIV clinical trials 20110101

• Virally mediated gene manipulation in the adult CNS.

  Frontiers in molecular neuroscience 20110101

• Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?

  Patient preference and adherence 20110101

• Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects.

  Acta naturae 20110101

• Screening of Potential HIV-1 Inhibitors/Replication Blockers Using Secure Lentiviral in Vitro System.

  Acta naturae 20110101

• Gyrase B inhibitor impairs HIV-1 replication by targeting Hsp90 and the capsid protein.

  The Journal of biological chemistry 20101210

• Effect of raltegravir on the pharmacokinetics of methadone.

  Journal of clinical pharmacology 20101201

• The evaluation of catechins that contain a galloyl moiety as potential HIV-1 integrase inhibitors.

  Clinical immunology (Orlando, Fla.) 20101201

• Integrase inhibitors in the treatment of HIV-1 infection.

  The Journal of antimicrobial chemotherapy 20101201

• Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.

  Antiviral research 20101201

• Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.

  Therapeutic drug monitoring 20101201

• Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks.

  AIDS research and human retroviruses 20101201

• HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.

  AIDS research and human retroviruses 20101201

• Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.

  Viruses 20101201

• Update of the drug resistance mutations in HIV-1: December 2010.

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20101201

• Emergence of raltegravir-resistant HIV-1 in the central nervous system.

  International journal of STD & AIDS 20101201

• A report from the XVIII International AIDS Conference. (July 18-23, 2010-Vienna, Austria).

  Drugs of today (Barcelona, Spain : 1998) 20101201

• Modeling the HIV-1 Intasome: A Prototype View of the Target of Integrase Inhibitors.

  Viruses 20101201

• Development of the next generation of HIV-1 integrase inhibitors: pyrazolone as a novel inhibitor scaffold.

  Bioorganic & medicinal chemistry letters 20101115

• Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.

  AIDS (London, England) 20101113

• Raltegravir-induced cerebellar ataxia.

  AIDS (London, England) 20101113

• HIV-1 integrase inhibitors: 2007-2008 update.

  Medicinal research reviews 20101101

• HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS.

  Journal of molecular and cellular cardiology 20101101

• Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.

  The Journal of antimicrobial chemotherapy 20101101

• Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.

  The Journal of antimicrobial chemotherapy 20101101

• Simultaneous pancreas-kidney transplantation in HIV-infected patients: a case report and literature review.

  Transplantation proceedings 20101101

• Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature.

  International journal of STD & AIDS 20101101

• First-line raltegravir. No evidence of comparative effectiveness.

  Prescrire international 20101101

• Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.

  AIDS (London, England) 20101023

• Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.

  AIDS (London, England) 20101023

• Antiretroviral drugs.

  Current opinion in pharmacology 20101001

• Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.

  Journal of acquired immune deficiency syndromes (1999) 20101001

• Characterization of integrase region polymorphisms in HIV type 1 CRF06_cpx viruses in treatment-naive patients in Estonia.

  AIDS research and human retroviruses 20101001

• Development of integrase inhibitors of quinolone acid derivatives for treatment of AIDS: an overview.

  Mini reviews in medicinal chemistry 20101001

• Acute promyelocytic leukemia in HIV-infected adults: a case report and review of therapeutic considerations.

  Clinical lymphoma, myeloma & leukemia 20101001

• Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors.

  Biochemistry 20100928

• Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen.

  AIDS (London, England) 20100924

• High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women.

  AIDS (London, England) 20100924

• HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays.

  AIDS (London, England) 20100910

• Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.

  Drugs 20100910

• Drug-drug interactions between raltegravir and pravastatin in healthy volunteers.

  Journal of acquired immune deficiency syndromes (1999) 20100901

• Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.

  Journal of acquired immune deficiency syndromes (1999) 20100901

• Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor.

  Journal of virology 20100901

• Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy.

  The Journal of antimicrobial chemotherapy 20100901

• Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice.

  Current HIV research 20100901

• Discovery of potent HIV integrase inhibitors active against raltegravir resistant viruses.

  Bioorganic & medicinal chemistry letters 20100901

• Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.

  Expert opinion on drug metabolism & toxicology 20100901

• Novel integrase inhibitors for HIV.

  Expert opinion on investigational drugs 20100901

• [Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor].

  Medecine et maladies infectieuses 20100901

• Bunyaviridae RNA polymerases (L-protein) have an N-terminal, influenza-like endonuclease domain, essential for viral cap-dependent transcription.

  PLoS pathogens 20100901

• Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20100801

• Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways.

  The Journal of pharmacology and experimental therapeutics 20100801

• Methadone, buprenorphine, and street drug interactions with antiretroviral medications.

  Current HIV/AIDS reports 20100801

• Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study.

  International journal of clinical practice 20100801

• The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.

  PLoS medicine 20100801

• Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.

  AIDS (London, England) 20100717

• Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults.

  AIDS (London, England) 20100717

• Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.

  Virology 20100705

• Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients.

  Scandinavian journal of infectious diseases 20100701

• Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution.

  The Journal of infection 20100701

• Resistance to integrase inhibitors.

  Viruses 20100701

• Authentic HIV-1 integrase inhibitors.

  Future medicinal chemistry 20100701

• Structural properties of HIV integrase. Lens epithelium-derived growth factor oligomers.

  The Journal of biological chemistry 20100625

• HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.

  The Journal of antimicrobial chemotherapy 20100601

• Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.

  PLoS pathogens 20100601

• Persistent prurigo nodularis responsive to initiation of combination therapy with raltegravir.

  Archives of dermatology 20100601

• Safe co-administration of raltegravir, pegylated-interferon and, ribavirin in HIV individuals with hepatitis C virus-related liver damage.

  AIDS (London, England) 20100515

• Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.

  Biochemistry 20100504

• Assessment of the susceptibility of mutant HIV-1 to antiviral agents.

  Journal of virological methods 20100501

• Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir.

  The Journal of antimicrobial chemotherapy 20100501

• Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.

  Antiviral research 20100501

• Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.

  The Annals of pharmacotherapy 20100501

• Inhibition of HIV-1 replication by isoxazolidine and isoxazole sulfonamides.

  Chemical biology & drug design 20100501

• Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.

  British journal of clinical pharmacology 20100501

• Retrovirus Integrase-DNA Structure Elucidates Concerted Integration Mechanisms.

  Viruses 20100501

• [Integrase inhibitor: raltegravir also as first line therapy].

  MMW Fortschritte der Medizin 20100429

• [Raltegravir: initially as effective as standard therapy].

  MMW Fortschritte der Medizin 20100429

• Chemistry and structure-activity relationship of the styrylquinoline-type HIV integrase inhibitors.

  Molecules (Basel, Switzerland) 20100427

• Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures.

  Journal of acquired immune deficiency syndromes (1999) 20100401

• Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.

  Journal of acquired immune deficiency syndromes (1999) 20100401

• HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

  Nature medicine 20100401

• Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.

  Journal of acquired immune deficiency syndromes (1999) 20100401

• A single-center cohort experience of raltegravir in salvage patients failing therapy.

  Journal of acquired immune deficiency syndromes (1999) 20100401

• Natural polymorphisms of integrase among HIV type 1-infected South African patients.

  AIDS research and human retroviruses 20100401

• Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.

  AIDS (London, England) 20100327

• High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors.

  AIDS (London, England) 20100327

• Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients.

  AIDS (London, England) 20100327

• A dynamic model of HIV integrase inhibition and drug resistance.

  Journal of molecular biology 20100326

• Raltegravir: in treatment-naive patients with HIV-1 infection.

  Drugs 20100326

• Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100315

• Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100315

• Central nervous system T-cell lymphoma in acquired immunodeficiency syndrome.

  British journal of haematology 20100301

• Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.

  The Journal of antimicrobial chemotherapy 20100301

• Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells.

  The Journal of antimicrobial chemotherapy 20100301

• Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.

  The Journal of antimicrobial chemotherapy 20100301

• Raltegravir: is a 400 mg once-daily dose enough?

  The Journal of antimicrobial chemotherapy 20100301

• HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.

  International journal of STD & AIDS 20100301

• Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir.

  Scandinavian journal of infectious diseases 20100301

• Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20100301

• [Advance and perspective of antiretroviral therapy].

  Nihon rinsho. Japanese journal of clinical medicine 20100301

• [Current topics on drug-resistant HIV in Japan].

  Nihon rinsho. Japanese journal of clinical medicine 20100301

• Drug-class specific impact of antivirals on the reproductive capacity of HIV.

  PLoS computational biology 20100301

• Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100215

• Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers.

  Cancer chemotherapy and pharmacology 20100201

• Quantification of raltegravir (MK0518) in human plasma by high-performance liquid chromatography with photodiode array detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100201

• New therapeutic strategies for raltegravir.

  The Journal of antimicrobial chemotherapy 20100201

• Raltegravir-based HAART regimen in a patient with large B-cell lymphoma.

  The Annals of pharmacotherapy 20100201

• Expanded postexposure prophylaxis for simultaneous multiple source HIV exposure in a health-care worker.

  International journal of STD & AIDS 20100201

• GSK-1349572, a novel integrase inhibitor for the treatment of HIV infection.

  Current opinion in investigational drugs (London, England : 2000) 20100201

• [The newest developments in anti-HIV-1 drugs].

  Yao xue xue bao = Acta pharmaceutica Sinica 20100201

• Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.

  Lancet (London, England) 20100130

• A case of rhabdomiolysis associated with raltegravir use.

  AIDS (London, England) 20100128

• LCMS using a hybrid quadrupole time of flight mass spectrometer for impurity identification during process chemical development of a novel integrase inhibitor.

  Journal of pharmaceutical and biomedical analysis 20100105

• The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.

  AIDS (London, England) 20100102

• Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.

  Antiviral research 20100101

• Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy.

  Antiviral research 20100101

• Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100101

• Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.

  Journal of medical virology 20100101

• Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20100101

• Integrase inhibitors: a novel class of antiretroviral agents.

  The Annals of pharmacotherapy 20100101

• Improving first-line antiretroviral therapy in resource-limited settings.

  Current opinion in HIV and AIDS 20100101

• Genetic diversity on the integrase region of the pol gene among HIV type 1-infected patients naive for integrase inhibitors in São Paulo City, Brazil.

  AIDS research and human retroviruses 20100101

• Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir.

  British journal of clinical pharmacology 20100101

• Towards a Patent Pool for HIV Medicines: The Background.

  The open AIDS journal 20100101

• Patent Pooling for Promoting Access to Antiretroviral Drugs (ARVs) - A Strategic Option for India.

  The open AIDS journal 20100101

• Pooling ARV Drug Patents: A Pro-Access Fitting Strategy?

  The open AIDS journal 20100101

• Profile of etravirine for the treatment of HIV infection.

  Therapeutics and clinical risk management 20100101

• Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.

  PloS one 20100101

• Designing ARVs Patent Pool Up to Trade & Policy Evolutionary Dynamics.

  The open AIDS journal 20100101

• [Approach to establishing and evaluating clinical relevance of drug interactions in HIV patients: 2009 update].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20100101

• Decreased NK Cell FcRgamma in HIV-1 infected individuals receiving combination antiretroviral therapy: a cross sectional study.

  PloS one 20100101

• Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.

  Retrovirology 20100101

• [Analysis of HIV-1 integrase gene polymorphism in an HIV-infected population from the nosocomial outbreak of HIV infection in the south of Russia in 1989].

  Voprosy virusologii 20100101

• Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome.

  PloS one 20100101

• The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.

  Antiviral therapy 20100101

• The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions.

  PloS one 20100101

• Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity.

  European journal of medical research 20100101

• Optimal management of cytomegalovirus retinitis in patients with AIDS.

  Clinical ophthalmology (Auckland, N.Z.) 20100101

• Expression of Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes.

  Retrovirology 20100101

• Semen may harbor HIV despite effective HAART: another piece in the puzzle.

  PloS one 20100101

• Recent key advances in human immunodeficiency virus medicine and implications for China.

  AIDS research and therapy 20100101

• 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention: summary of key research and implications for policy and practice - clinical sciences.

  Journal of the International AIDS Society 20100101

• ICAAC update. Three new drugs in development, plus Isentress with Reyataz.

  Positively aware : the monthly journal of the Test Positive Aware Network 20100101

• Anticipating and blocking HIV-1 escape by second generation antiviral shRNAs.

  Retrovirology 20100101

• Resistance to HIV-1 integrase inhibitors: A structural perspective.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20100101

• Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.

  Antiviral therapy 20100101

• Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time.

  PloS one 20100101

• Peptides derived from the HIV-1 integrase promote HIV-1 infection and multi-integration of viral cDNA in LEDGF/p75-knockdown cells.

  Virology journal 20100101

• Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice.

  European journal of medical research 20100101

• Lack of detection of XMRV in seminal plasma from HIV-1 infected men in The Netherlands.

  PloS one 20100101

• An examination of drug-drug interactions with raltegravir.

  HIV clinician 20100101

• Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors.

  Retrovirology 20100101

• From bench to clinic: accessing promising investigational medications for patients with HIV infection in an urban family health center.

  Journal of the American Board of Family Medicine : JABFM 20100101

• Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine.

  Antiviral therapy 20100101

• Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen.

  Clinical epidemiology 20100101

• Gut inflammation in chronic fatigue syndrome.

  Nutrition & metabolism 20100101

• Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease.

  Retrovirology 20100101

• The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children.

  BMC pediatrics 20100101

• Progress in antiretroviral drug delivery using nanotechnology.

  International journal of nanomedicine 20100101

• Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial.

  HIV clinical trials 20100101

• Routine HIV screening in France: clinical impact and cost-effectiveness.

  PloS one 20100101

• Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.

  Antiviral therapy 20100101

• Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models.

  PloS one 20100101

• DNA suspension arrays: silencing discrete artifacts for high-sensitivity applications.

  PloS one 20100101

• In vitro HIV-1 selective integration into the target sequence and decoy-effect of the modified sequence.

  PloS one 20100101

• Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir.

  Retrovirology 20100101

• A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trial.

  HIV clinical trials 20100101

• Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138).

  HIV clinical trials 20100101

• Quantitative PCR used to assess HIV-1 integration and 2-LTR circle formation in human macrophages, peripheral blood lymphocytes and a CD4+ cell line.

  Virology journal 20100101

• Virologic and immunologic effectiveness of tipranavir/ritonavir (TPV/r)- versus darunavir/ritonavir (DRV/r)-based regimens in clinical practice.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20100101

• Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals.

  Antiviral therapy 20100101

• Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution.

  AIDS research and therapy 20100101

• Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009.

  PloS one 20100101

• Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.

  PharmacoEconomics 20100101

• Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.

  PloS one 20100101

• The HIV-1 integrase α4-helix involved in LTR-DNA recognition is also a highly antigenic peptide element.

  PloS one 20100101

• Resistance to inhibitors of the human immunodeficiency virus type 1 integration.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20100101

• Torsade de Pointes due to Methadone Use in a Patient with HIV and Hepatitis C Coinfection.

  Cardiology research and practice 20100101

• [Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens].

  Terapevticheskii arkhiv 20100101

• Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems.

  Cholesterol 20100101

• Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection.

  Infection and drug resistance 20100101

• Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy.

  Infection and drug resistance 20100101

• Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1.

  HIV/AIDS (Auckland, N.Z.) 20100101

• The effect of aging, nutrition, and exercise during HIV infection.

  HIV/AIDS (Auckland, N.Z.) 20100101

• Management of chronic diarrhea in HIV-infected patients: current treatment options, challenges and future directions.

  HIV/AIDS (Auckland, N.Z.) 20100101

• Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20091201

• Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples.

  Therapeutic drug monitoring 20091201

• An HIV-1 integrase genotype assay for the detection of drug resistance mutations.

  Sexual health 20091201

• A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate.

  Expert opinion on pharmacotherapy 20091201

• The SWITCHMRK studies: substitution of lopinavir/ritonavir with raltegravir in HIV-positive individuals.

  Expert review of anti-infective therapy 20091201

• Antiretroviral therapy: new drugs, formulations, ideas, and strategies.

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20091201

• HIV-1 Integrase-DNA Recognition Mechanisms.

  Viruses 20091201

• Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus.

  AIDS (London, England) 20091113

• [Features and the method of application of a CCR5 antagonist, a new integrase inhibitor].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20091110

• [Status of anti-HIV drug development and an overview of combined chemotherapy].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20091110

• A combined genotypic and phenotypic human immunodeficiency virus type 1 recombinant virus assay for the reverse transcriptase and integrase genes.

  Journal of virological methods 20091101

• Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.

  Journal of acquired immune deficiency syndromes (1999) 20091101

• Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.

  Journal of acquired immune deficiency syndromes (1999) 20091101

• Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug.

  The Journal of antimicrobial chemotherapy 20091101

• Lack of specificity for the analysis of raltegravir using online sample clean-up liquid chromatography-electrospray tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091101

• Efavirenz: a decade of clinical experience in the treatment of HIV.

  The Journal of antimicrobial chemotherapy 20091101

• High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20091101

• Maraviroc and raltegravir.

  British journal of clinical pharmacology 20091101

• Integrase inhibitors in salvage therapy regimens for HIV-1 infection.

  Current opinion in HIV and AIDS 20091101

• Resistance to novel drug classes.

  Current opinion in HIV and AIDS 20091101

• The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy.

  AIDS (London, England) 20091023

• Elvitegravir: a new HIV integrase inhibitor.

  Antiviral chemistry & chemotherapy 20091019

• Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20091015

• Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20091001

• Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient.

  The Journal of antimicrobial chemotherapy 20091001

• New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.

  Expert opinion on pharmacotherapy 20091001

• The effect of raltegravir on the glucuronidation of lamotrigine.

  Journal of clinical pharmacology 20091001

• In search of second-generation HIV integrase inhibitors: targeting integration beyond strand transfer.

  Future medicinal chemistry 20091001

• Raltegravir: a new choice in HIV and new chances for research.

  Lancet (London, England) 20090905

• Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.

  Lancet (London, England) 20090905

• Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors.

  ChemMedChem 20090901

• Acute onset insomnia associated with the initiation of raltegravir: a report of two cases and literature review.

  AIDS patient care and STDs 20090901

• New developments in HIV drug resistance.

  The Journal of antimicrobial chemotherapy 20090901

• The history of antiretrovirals: key discoveries over the past 25 years.

  Reviews in medical virology 20090901

• FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients.

  AIDS alert 20090901

• Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center.

  Bioorganic & medicinal chemistry letters 20090815

• A cascade approach to cyclic aminonitrones: reaction discovery, mechanism, and scope.

  Organic letters 20090806

• Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study.

  Journal of acquired immune deficiency syndromes (1999) 20090801

• Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus.

  Medical microbiology and immunology 20090801

• Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20090801

• N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[1,2-a]pyrimidine-2-carboxamides a novel class of potent HIV-1 integrase inhibitors.

  Bioorganic & medicinal chemistry letters 20090801

• Dynamics of raltegravir resistance profile in an HIV type 2-infected patient.

  AIDS research and human retroviruses 20090801

• Raltegravir as effective as efavirenz in 144-week data.

  AIDS patient care and STDs 20090801

• FDA notifications. Raltegravir indication extended for treatment-naive patients.

  AIDS alert 20090801

• Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study.

  AIDS (London, England) 20090731

• An analysis of current pharmaceutical industry practices for making clinical trial results publicly accessible.

  Contemporary clinical trials 20090701

• Exploration of novel thiobarbituric acid-, rhodanine- and thiohydantoin-based HIV-1 integrase inhibitors.

  Bioorganic & medicinal chemistry letters 20090701

• Evolution of raltegravir resistance during therapy.

  The Journal of antimicrobial chemotherapy 20090701

• Analysis of binding parameters of HIV-1 integrase inhibitors: correlates of drug inhibition and resistance.

  Bioorganic & medicinal chemistry 20090701

• Cost-effectiveness analysis of raltegravir in treatment-experienced HIV type 1-infected patients in Spain.

  AIDS research and human retroviruses 20090701

• Switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 24 weeks in a Montreal cohort.

  Journal of acquired immune deficiency syndromes (1999) 20090701

• Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.

  Clinical pharmacology and therapeutics 20090601

• Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.

  The Journal of antimicrobial chemotherapy 20090601

• Etravirine: new drug. Multidrug-resistant HIV: another option.

  Prescrire international 20090601

• Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients.

  Drugs 20090529

• Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil.

  Journal of acquired immune deficiency syndromes (1999) 20090501

• Treatment of HIV infection with raltegravir.

  Expert opinion on pharmacotherapy 20090501

• [Medication change due to side effects or possible long-term complications. Side effect management with vision].

  MMW Fortschritte der Medizin 20090430

• [New antiretroviral drug classes in HIV therapy].

  MMW Fortschritte der Medizin 20090430

• Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases.

  AIDS (London, England) 20090427

• Tricyclic HIV integrase inhibitors V. SAR studies on the benzyl moiety.

  Bioorganic & medicinal chemistry letters 20090415

• A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090415

• Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.

  International journal of antimicrobial agents 20090401

• Quantitative prediction of human clearance guiding the development of Raltegravir (MK-0518, isentress) and related HIV integrase inhibitors.

  Drug metabolism and disposition: the biological fate of chemicals 20090401

• Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.

  The Journal of antimicrobial chemotherapy 20090401

• Raltegravir: the first HIV type 1 integrase inhibitor.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090401

• Simultaneous determination of maraviroc and raltegravir in human plasma by HPLC-UV.

  IUBMB life 20090401

• FDA notifications. FDA grants approval for raltegravir.

  AIDS alert 20090401

• CROI 2009: a few key presentations on antiretroviral therapy.

  The AIDS reader 20090401

• Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use.

  The AIDS reader 20090401

• Mechanistic and pharmacological analyses of HIV-1 integration.

  Methods (San Diego, Calif.) 20090401

• Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia.

  PLoS pathogens 20090401

• Report from the 16th Conference on Retroviruses and Opportunistic Infections. SWITCHMRK: an avoidable raltegravir disaster.

  Journal watch. AIDS clinical care 20090401

• Pharmacokinetics of darunavir, etravirine and raltegravir in an HIV-infected patient on haemodialysis.

  AIDS (London, England) 20090327

• Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.

  Antimicrobial agents and chemotherapy 20090301

• A paediatric case of acute liver failure associated with efavirenz-based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation.

  The Journal of antimicrobial chemotherapy 20090301

• Timing the emergence of resistance to anti-HIV drugs with large genetic barriers.

  PLoS computational biology 20090301

• Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay.

  AIDS research and human retroviruses 20090301

• The fusion inhibitor enfuvirtide in recent antiretroviral strategies.

  Current opinion in HIV and AIDS 20090301

• Two studies show Kaletra and Isentress similarly suppress HIV, yet have different side effects.

  Project Inform perspective 20090301

• Isentress equal to Sustiva in first line therapy.

  Project Inform perspective 20090301

• Potent inhibitors of HIV-1 integrase display a two-step, slow-binding inhibition mechanism which is absent in a drug-resistant T66I/M154I mutant.

  Biochemistry 20090224

• Quantification of the HIV-integrase inhibitor raltegravir and detection of its main metabolite in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of high-performance liquid chromatography tandem mass spectrometry.

  Journal of pharmaceutical and biomedical analysis 20090220

• Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.

  AIDS (London, England) 20090220

• Effects of omeprazole on plasma levels of raltegravir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090215

• Pharmacologic aspects of new antiretroviral drugs.

  Current HIV/AIDS reports 20090201

• Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection?

  Journal of acquired immune deficiency syndromes (1999) 20090201

• New approaches for inhibiting HIV integrase: a journey beyond the active site.

  Current opinion in investigational drugs (London, England : 2000) 20090201

• Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection.

  Current opinion in investigational drugs (London, England : 2000) 20090201

• Raltegravir and etravirine are active against HIV type 1 group O.

  AIDS research and human retroviruses 20090201

• [Raltegravir as first integrase inhibitor in an HIV-infection].

  Nederlands tijdschrift voor geneeskunde 20090131

• Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses.

  Biochemistry 20090113

• Emerging pharmacology: inhibitors of human immunodeficiency virus integration.

  Annual review of pharmacology and toxicology 20090101

• Systematic analysis of insertions and deletions specific to nematode proteins and their proposed functional and evolutionary relevance.

  BMC evolutionary biology 20090101

• Novel targets for antiretroviral therapy: clinical progress to date.

  Drugs 20090101

• HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure.

  Retrovirology 20090101

• Top stories of 2008. Beyond abacavir/3TC: good news on first-line regimens.

  AIDS clinical care 20090101

• Top stories of 2008. Newer drugs strikingly effective when given together.

  AIDS clinical care 20090101

• Raltegravir, elvitegravir, and metoogravir: the birth of 'me-too' HIV-1 integrase inhibitors.

  Retrovirology 20090101

• Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• Characterization and structural analysis of HIV-1 integrase conservation.

  AIDS reviews 20090101

• Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.

  Antiviral therapy 20090101

• Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• HIV dynamics and integrase inhibitors.

  Antiviral chemistry & chemotherapy 20090101

• Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir.

  Antiviral therapy 20090101

• Role of atazanavir in the treatment of HIV infection.

  Therapeutics and clinical risk management 20090101

• New hexahydrodiazocino-naphthyridine triones as HIV-1 integrase inhibitors: WO2008048538 A1.

  Expert opinion on therapeutic patents 20090101

• Drug interactions with new and investigational antiretrovirals.

  Clinical pharmacokinetics 20090101

• Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection.

  Therapeutics and clinical risk management 20090101

• HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations.

  Journal of molecular recognition : JMR 20090101

• Anti-HIV agents. Atazanavir and raltegravir--an interesting combination.

  TreatmentUpdate 20090101

• Pharmacotherapy of pediatric and adolescent HIV infection.

  Therapeutics and clinical risk management 20090101

• Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.

  Therapeutics and clinical risk management 20090101

• Raltegravir cerebrospinal fluid concentrations in HIV-1 infection.

  PloS one 20090101

• Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals.

  HIV clinical trials 20090101

• Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland.

  HIV clinical trials 20090101

• HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.

  PloS one 20090101

• Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes.

  Retrovirology 20090101

• Progress in basic and clinical research on HIV resistance: report on the XVIII International HIV Drug Resistance Workshop.

  Antiviral therapy 20090101

• Raltegravir: molecular basis of its mechanism of action.

  European journal of medical research 20090101

• Drug-drug interactions with raltegravir.

  European journal of medical research 20090101

• Raltegravir in treatment naive patients.

  European journal of medical research 20090101

• The use of integrase inhibitors in treatment-experienced patients.

  European journal of medical research 20090101

• Raltegravir use in special populations.

  European journal of medical research 20090101

• HIV resistance to raltegravir.

  European journal of medical research 20090101

• Efficacy and safety of an NRTI-sparing dual regimen of raltegravir and ritonavir-boosted protease inhibitor in a triple antiretroviral class-experienced population.

  HIV clinical trials 20090101

• Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007.

  PloS one 20090101

• [Desensitization to tipranavir caused by toxicodermia].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101

• Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.

  HIV clinical trials 20090101

• Raltegravir: The evidence of its therapeutic value in HIV-1 infection.

  Core evidence 20090101

• Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection.

  Core evidence 20090101

• Optimal use of raltegravir (Isentress(R)) in the treatment of HIV-infected adults - Canadian consensus guidelines.

  The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale 20090101

• Profile of darunavir in the management of treatment-experienced HIV patients.

  HIV/AIDS (Auckland, N.Z.) 20090101

• Role of darunavir in the management of HIV infection.

  HIV/AIDS (Auckland, N.Z.) 20090101

• Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.

  HIV/AIDS (Auckland, N.Z.) 20090101

• Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.

  Journal of medicinal chemistry 20081225

• An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients.

  Therapeutic drug monitoring 20081201

• Report from the 2008 joint ICAAC/IDSA meeting. Raltegravir vs. efavirenz in treatment-naive patients.

  AIDS clinical care 20081201

• Report from the 2008 joint ICAAC/IDSA meeting. More on raltegravir: resistance and mechanisms of action.

  AIDS clinical care 20081201

• Raltegravir for postexposure prophylaxis following occupational exposure to HIV.

  AIDS (London, England) 20081130

• Elevated alkaline phosphatase with raltegravir in a treatment experienced HIV patient.

  AIDS (London, England) 20081112

• An accurate and precise high-performance liquid chromatography method for the rapid quantification of the novel HIV integrase inhibitor raltegravir in human blood plasma after solid phase extraction.

  Analytica chimica acta 20081103

• Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants.

  Antiviral research 20081101

• Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection.

  The Journal of antimicrobial chemotherapy 20081101

• HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.

  The Journal of antimicrobial chemotherapy 20081101

• Pharmacologic aspects of new antiretroviral drugs.

  Current infectious disease reports 20081101

• Darunavir-etravirine-raltegravir as salvage combination therapy in a heavily pretreated HIV-infected patient.

  AIDS patient care and STDs 20081101

• Raltegravir phase III study data released.

  AIDS patient care and STDs 20081101

• Trial will evaluate a once-daily dose of raltegravir.

  AIDS patient care and STDs 20081101

• Antiretroviral treatment update from the 17th International AIDS Conference.

  The AIDS reader 20081101

• [Raltegravir: the first HIV integrase inhibitor. Introduction].

  Enfermedades infecciosas y microbiologia clinica 20081101

• [How proviral DNA is integrated into the host cell DNA and how this process can be inhibited].

  Enfermedades infecciosas y microbiologia clinica 20081101

• [Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment].

  Enfermedades infecciosas y microbiologia clinica 20081101

• [Pharmacokinetics and interactions of raltegravir].

  Enfermedades infecciosas y microbiologia clinica 20081101

• [Efficacy of raltegravir: from healthy volunteers to phase III trials].

  Enfermedades infecciosas y microbiologia clinica 20081101

• [Secondary effects associated with raltegravir].

  Enfermedades infecciosas y microbiologia clinica 20081101

• [Resistance to integrase inhibitors].

  Enfermedades infecciosas y microbiologia clinica 20081101

• [Role of the new molecules in antiretroviral therapy. Position of raltegravir].

  Enfermedades infecciosas y microbiologia clinica 20081101

• Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.

  HIV medicine 20081001

• Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.

  AIDS (London, England) 20081001

• Discovery of 3-acetyl-4-hydroxy-2-pyranone derivatives and their difluoridoborate complexes as a novel class of HIV-1 integrase inhibitors.

  Bioorganic & medicinal chemistry 20081001

• [New CCR5 inhibitor antiretroviral drugs and integrase inhibitors].

  Revista clinica espanola 20081001

• Raltegravir: the first HIV integrase inhibitor.

  Clinical therapeutics 20081001

• [Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].

  Enfermedades infecciosas y microbiologia clinica 20081001

• Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.

  Therapeutics and clinical risk management 20081001

• Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.

  Journal of medicinal chemistry 20080925

• Exacerbation of depression associated with starting raltegravir: a report of four cases.

  AIDS (London, England) 20080912

• Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility.

  AIDS (London, England) 20080912

• Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.

  Biochemistry 20080909

• An improved relaxed complex scheme for receptor flexibility in computer-aided drug design.

  Journal of computer-aided molecular design 20080901

• A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.

  Antiviral research 20080901

• HIV infection in the elderly.

  Clinical interventions in aging 20080901

• Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

  JAMA 20080806

• Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.

  Antimicrobial agents and chemotherapy 20080801

• Raltegravir: the first in a new class of integrase inhibitors for the treatment of HIV.

  Expert review of anti-infective therapy 20080801

• Raltegravir, an HIV-1 integrase inhibitor for HIV infection.

  Current opinion in investigational drugs (London, England : 2000) 20080801

• A conventional LC-MS method developed for the determination of plasma raltegravir concentrations.

  Biological & pharmaceutical bulletin 20080801

• Combating HIV resistance - focus on darunavir.

  Therapeutics and clinical risk management 20080801

• Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.

  Prescrire international 20080801

• The Relationship Between HIV Infection and Cardiovascular Disease.

  Current cardiology reviews 20080801

• Raltegravir with optimized background therapy for resistant HIV-1 infection.

  The New England journal of medicine 20080724

• Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

  The New England journal of medicine 20080724

• Severe rhabdomyolysis associated with raltegravir use.

  AIDS (London, England) 20080711

• Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase.

  Journal of medicinal chemistry 20080710

• Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080701

• New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.

  The Journal of infection 20080701

• New drugs08, part 2.

  Nursing 20080701

• Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients.

  AIDS research and human retroviruses 20080701

• How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals.

  Drug discovery today 20080701

• Integrase inhibitors for the treatment of HIV infection.

  Current opinion in drug discovery & development 20080701

• Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen.

  AIDS (London, England) 20080619

• Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval.

  Journal of clinical pharmacology 20080601

• Integrase inhibitors: a clinical review of raltegravir and elvitegravir.

  Journal of HIV therapy 20080601

• Raltegravir treatment response in an HIV-2 infected patient: a case report.

  AIDS (London, England) 20080531

• A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080515

• Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high-performance liquid chromatography with fluorescence detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080515

• Successful rescue therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an hiv-infected patient failing all four classes of antiretroviral drugs.

  AIDS patient care and STDs 20080501

• Complexity of interactions between voriconazole and antiretroviral agents.

  The Annals of pharmacotherapy 20080501

• A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series.

  Bioorganic & medicinal chemistry letters 20080501

• Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV.

  Current opinion in HIV and AIDS 20080501

• Raltegravir: first in class HIV integrase inhibitor.

  Therapeutics and clinical risk management 20080401

• 'One pill, once daily': what clinicians need to know about Atriplatrade mark.

  Therapeutics and clinical risk management 20080401

• Quinolone 3-carboxylic acid pharmacophore: design of second generation HIV-1 integrase inhibitors.

  Journal of medicinal chemistry 20080313

• Raltegravir: an integrase inhibitor for HIV-1.

  Expert opinion on investigational drugs 20080301

• [New drugs for HIV infection].

  Revue de l'infirmiere 20080301

• Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation.

  AIDS (London, England) 20080219

• Tricyclic HIV integrase inhibitors: potent and orally bioavailable C5-aza analogs.

  Bioorganic & medicinal chemistry letters 20080215

• Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.

  Clinical pharmacology and therapeutics 20080201

• Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation.

  Journal of clinical pharmacology 20080201

• Novel druggable hot spots in avian influenza neuraminidase H5N1 revealed by computational solvent mapping of a reduced and representative receptor ensemble.

  Chemical biology & drug design 20080201

• [New therapeutic options in protracted HIV-infected patients with virological failure].

  Medicina clinica 20080126

• Two new drugs for HIV infection.

  The Medical letter on drugs and therapeutics 20080114

• Raltegravir.

  Drugs 20080101

• Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection.

  Expert opinion on investigational drugs 20080101

• Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection.

  Pharmacotherapy 20080101

• New drugs: doripenem, raltegravir, and ixabepilone.

  Journal of the American Pharmacists Association : JAPhA 20080101

• The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal.

  Retrovirology 20080101

• Drug 9AA reactivates p21/Waf1 and Inhibits HIV-1 progeny formation.

  Virology journal 20080101

• The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection.

  Progress in medicinal chemistry 20080101

• Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Advances in antiretroviral therapy.

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20080101

• HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

  AIDS reviews 20080101

• Emerging therapies for hepatitis C and HIV in drug abusers: drugs and strategies.

  Journal of addictive diseases 20080101

• Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors.

  Retrovirology 20080101

• Comparing two integrase inhibitors. The first head-to-head study comparing raltegravir and elvitegravir.

  Positively aware : the monthly journal of the Test Positive Aware Network 20080101

• Emerging resistance profiles of newly approved antiretroviral drugs.

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20080101

• Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.

  Antiviral therapy 20080101

• Integrase and integration: biochemical activities of HIV-1 integrase.

  Retrovirology 20080101

• No residual activity of raltegravir after development of 148 complex mutations in vivo.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20080101

• Broad advances in understanding HIV resistance to antiretrovirals: report on the XVII International HIV Drug Resistance Workshop.

  Antiviral therapy 20080101

• Raltegravir in the management of HIV-infected patients.

  Drug design, development and therapy 20080101

• Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1.

  Drugs of today (Barcelona, Spain : 1998) 20071201

• Raltegravir, a new HIV integrase inhibitor.

  AIDS clinical care 20071201

• FDA notifications. Accelerated approval for raltegravir tablets.

  AIDS alert 20071201

• Substituted 2-pyrrolinone inhibitors of HIV-1 integrase.

  Bioorganic & medicinal chemistry letters 20071115

• Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.

  AIDS (London, England) 20071112

• Mirabamides A-D, depsipeptides from the sponge Siliquariaspongia mirabilis that inhibit HIV-1 fusion.

  Journal of natural products 20071101

• [Raltegravir an integrase inhibitor--a great leap forward within reach].

  Medizinische Monatsschrift fur Pharmazeuten 20071101

• FDA approves raltegravir tablets.

  AIDS patient care and STDs 20071101

• How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection.

  European journal of medical research 20071015

• Antiviral drugs in the treatment of AIDS: what is in the pipeline ?

  European journal of medical research 20071015

• Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.

  Journal of acquired immune deficiency syndromes (1999) 20071001

• Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070915

• Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme.

  Drug metabolism and disposition: the biological fate of chemicals 20070901

• Studies of metabolism and disposition of potent human immunodeficiency virus (HIV) integrase inhibitors using 19F-NMR spectroscopy.

  Xenobiotica; the fate of foreign compounds in biological systems 20070901

• 48-week data on raltegravir in naive patients.

  AIDS patient care and STDs 20070901

• Approval recommended for raltegravir in experienced patients.

  AIDS patient care and STDs 20070901

• Pivotal moments in HIV treatment: the 14th CROI.

  The AIDS reader 20070501

• Advances in HIV therapeutics: the 14th CROI.

  The AIDS reader 20070501

• Raltegravir: a new antiretroviral class for salvage therapy.

  Lancet (London, England) 20070414

• Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.

  Lancet (London, England) 20070414

• Researchers buoyed by novel HIV drugs: will expand drug arsenal against resistant virus.

  JAMA 20070411

• New drugs offer options.

  The AIDS reader 20070401

• Raltegravir demonstrates potency.

  AIDS patient care and STDs 20070401

• Anti-HIV agents. New drugs, new hope, old lessons.

  TreatmentUpdate 20070201

• Anti-HIV agents. Integrase inhibitor raltegravir makes its mark.

  TreatmentUpdate 20070201

• Anti-HIV agents. Raltegravir--other issues.

  TreatmentUpdate 20070201

• Advances in antiretroviral therapy.

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20070101

• Expanded access drug profile: raltegravir (RAL, MK-0518).

  The Hopkins HIV report : a bimonthly newsletter for healthcare providers 20070101

• Antiretroviral treatment of HIV infection: Swedish recommendations 2007.

  Scandinavian journal of infectious diseases 20070101

• Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS.

  Retrovirology 20070101

• Anti-HIV agents. New drugs--hope and a degree of caution.

  TreatmentUpdate 20070101

• Targeting human immunodeficiency virus type 1 assembly, maturation and budding.

  Drug target insights 20070101

• Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.

  Journal of acquired immune deficiency syndromes (1999) 20061215

• Fuzeon combination highly effective.

  AIDS patient care and STDs 20061201

• Meeting report. Report from ICAAC.

  AIDS clinical care 20061201

• XVI International AIDS Conference: Part 2.

  The AIDS reader 20061101

• AIDS 2006 - XVI International Conference. Time to deliver.

  IDrugs : the investigational drugs journal 20061001

• The latest in antiretroviral therapy.

  Drug news & perspectives 20061001

• The clinical pharmacology of antiretrovirals in development.

  Expert opinion on drug metabolism & toxicology 20060601

• Retrovirus meeting. Novel attacks on HIV move closer to reality.

  Science (New York, N.Y.) 20060217

• MK-0518 and GS-9137: two promising integrase inhibitors in the pipeline.

  BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation 20060101

• Integrase inhibitor MK-0518: Merck opens expanded-access program.

  AIDS treatment news 20060101

• Anti-HIV agents. Some drug interactions with Merck's integrase inhibitor.

  TreatmentUpdate 20060101

• Anti-HIV agents. Merck integrase inhibitor.

  TreatmentUpdate 20060101